YolTech Therapeutics announced last week that the first two patients have been dosed in a Phase 1 trial of YOLT-203, an in vivo CRISPR-based...

HuidaGene Therapeutics recently announced that the FDA has granted Orphan Drug Designation to its CRISPR-based therapeutic candidate, HG302. The...

Founded in 2011, Caribou Biosciences is developing novel allogeneic CAR-T cell and CAR-natural killer cell therapies to treat cancer. The UC Berkeley...

As the COVID-19 pandemic continues to evolve with fluctuating restrictions worldwide, mass vaccine rollouts and the emergence of new variants, it's...

This week’s update looks at a CRISPR-Cas12a-based detection method, developed in China as a confirmatory tool to aid SARS-CoV-2 diagnosis.